Infectious Disease

Pseudomonas Vaccine Program

Infections caused by multidrug-resistant (MDR) bacteria such as Pseudomonas aeruginosa (Pa) are a growing threat to human life. The World Health Organization (WHO) recently categorized Pa as a priority pathogen of the greatest risk to human health.  PA opportunistically infects diabetic wounds, cystic fibrosis airways, and medical materials (such as ventilators, bandages, and catheters), resulting in hospital acquired infections. Each year, fewer viable options are available to treat Pa infections due to drug resistance. No effective vaccine is available to prevent infection. A major hurdle to developing an effective Pa vaccine is identifying well conserved molecular targets from the wide range of Pa strains that infect humans which are amenable to immunization. 


Breakthrough research led by Dr. Pat Secor at the University of Montana and colleagues have found that approximately 84% of Pa isolates are infected by a filamentous bacteriophage (a virus that infects bacteria) called Pf. Vaccinating against the major coat protein (CoaB) of Pf virions prevents Pa from establishing an infection in a mouse wound model (Sweere, Science 2019). Using our proprietary vaccine adjuvant INI-2002, we, in collaboration with Dr. Secor, have developed a series of conjugate vaccines that target the well-conserved CoaB antigen found on the strains of Pf phage that infect diverse Pa isolates, including drug resistant strains.

Sweere JM, Van Belleghem JD, Ishak H, et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science 2019;363

MRSA Antibiotics

Microorganisms isolated from extreme environments have proven to be a good source for the discovery of novel, bioactive compounds. A co-culture of two extremophilic fungi, Penicillium fuscum and P. camembertii/clavigerum, that were isolated from a single sample of surface water from the Berkeley Pit Lake superfund site yielded a novel antibiotic, Berkeleylactone A (BA), with activity against methicillin resistant S. aureus (MRSA)It was also screened against several other gram-positive strains and demonstrated excellent anti-microbial activity. Screening against gram-negative strains demonstrated that the derivation of the core scaffold results in greatly enhanced gram-negative antibiotic activity without subsequent loss of gram-positive cytotoxicity.

Inimmune possesses an exclusive right to license BA and its derivatives for commercial use and is currently pursuing the development of this unique new class of compounds.

Vaccine Adjuvants

Vaccines are one of the most successful medical interventions in human history, saving 2.5 million lives per year and protecting millions more from severe illness and hospitalization, according to the WHO. Despite this incredible success, there are many infectious diseases for which effective vaccines do not currently exist.

One strategy to developing new or more protective vaccines is through the addition of adjuvants, which help activate the immune system. Inimmune is a leader in the discovery and development of vaccine adjuvants with over 20 years of expertise in their safe and effective use. Inimmune’s novel small molecule adjuvants can activate the immune system in specific ways to drive the right immune response to deliver protection against pathogens of interest.

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants. In addition, our formulations team has extensive expertise in tailoring vaccine delivery systems for these innate immune agonists, to match the route of administration and dosing required for a given indication.

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics.

Contact

© Copyright 2022 Inimmune. All Rights Reserved.

Website Design by Digital Marketing Missoula
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.

TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING